The Singapore-based digital health company Healint was acquired by Aptar Digital Health, a global provider of digital health solutions.
The acquisition of Healint is in line with Aptar Digital Health’s strategy to expand its neurology portfolio and fortify its global footprint for the implementation of digital health, the company said in a statement.
In addition to data collection and analysis based on artificial intelligence (AI), patient community management, patient activation, and digital diagnostics to aid in patient screening and identification are among the enhanced capabilities.
In addition, Healint’s capacity to carry out clinical trials globally and quickly enhances Aptar Digital Health’s current offerings to give pharmaceutical clients even more value.
“We are excited to welcome the Healint team and expand Aptar Digital Health’s product portfolio and capabilities to clinical trial management,
“With Healint, we now have the in-house expertise to cover the entire lifecycle of a drug, positioning Aptar Digital Health as a prominent leader in digital health for Central Nervous System conditions,” said Sai Shankar, President of Aptar Digital Health.
The president of Aptar Pharma, Gael Touya, stated that the acquisition fully aligns with Aptar Pharma’s primary goal of enhancing patient experiences and health outcomes. Aptar Digital Health and Healint’s combined expertise in creating cutting-edge solutions that empower patients in their disease journeys.
“The integration of Healint into Aptar Digital Health’s operations will commence immediately.”
In addition to strengthening its current offering by adding new services like clinical trial management tools, Aptar Digital Health is said to be expanding Healint’s platform to adjacent therapeutic indications in neurology and immunology.
“We are delighted to join the Aptar Digital Health team to better serve patients, healthcare professionals, and pharmaceutical companies,
“This acquisition will accelerate the development of our AI-powered precision medicine SaMD designed to augment existing treatment, thanks to unique datasets and scientific expertise,” said François Cadiou, Chief Executive Officer and Founder of Healint.
Healint was founded in 2013 and has gained recognition for its real-world evidence, virtual clinical studies, patient registries, and mobile apps, Clarrio and Migraine Buddy, which assist patients with neurological and immunological conditions.
Using self-input and sensor data at scale, interpreted via its proprietary AI, the company is a pioneer in multimodal health and Quality of Life (QoL) tracking and clinically validated data collection.
